Related Experiment Videos
Sertaconazole: in-vitro antifungal activity against vaginal and other superficial yeast isolates
A J Carrillo-Muñoz1, S Brió, G Quindós
1Dept. Microbiología, ACIA, Barcelona, Spain. acarrillo17@terra.es
Abstract:
The in vitro susceptibilities of 183 clinical yeast isolates to sertaconazole (STZ) were compared to their susceptibilities to clotrimazole (CTZ), econazole (ECZ), ketoconazole (KTZ), miconazole (MNZ), fluconazole (FLZ), itraconazole (ITZ), tioconazole (TCZ), amphotericin B (AMB) and flucytosine (5FC) by using a commercial agar diffusion method. Strains were isolated from vaginal and other superficial clinical samples (18 species of Candida and five strains belonging to other yeast genera). Only one strain (0.5%) was resistant to STZ out of 87.4% of susceptible strains (n=160). The percentage of susceptible strains was higher than those obtained with the other agents evaluated and the percentage of resistant strains was lower than for most of the other antifungals. The pattern of susceptibility of C. albicans to STZ, TCZ, ITZ and CLZ was similar and superior to the pattern of susceptibility of this species to MNZ, ECZ, FLZ, 5FC and KTZ. C. dubliniensis was more susceptible to STZ, MNZ, MNZ, FLZ, ITZ, CLZ than to TCZ, ECZ, 5FC, AMB or KTZ. Ten susceptible strains to STZ were resistant to FLZ and one strain was resistant to ITZ. The overall antifungal activity of STZ in vitro against a wide range of clinically important yeasts from vaginal and cutaneous samples indicates the therapeutic potential of this agent for the treatment of infections caused by these fungi. However, the activity of STZ and the clinical value of in vitro data need to be verified in human clinical trials.
Insights
Sertaconazole (STZ) demonstrated high in vitro antifungal activity against clinical yeast isolates, with only 0.5% resistance. This suggests STZ
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Superficial fungal infections, particularly those caused by yeasts, remain a significant clinical challenge.
- A wide array of antifungal agents are available, but resistance and varying efficacy necessitate ongoing research into new or improved treatments.
- Candida species and other yeasts are common etiological agents of vaginal and superficial cutaneous infections.
Purpose of the Study:
- To evaluate the in vitro antifungal activity of sertaconazole (STZ) against a diverse collection of clinical yeast isolates.
- To compare the susceptibility of these yeast strains to STZ with their susceptibility to ten other established antifungal agents.
- To assess the potential of STZ as a therapeutic option for superficial fungal infections.
Main Methods:
- A commercial agar diffusion method was employed to determine the in vitro susceptibilities of 183 clinical yeast isolates.
- Isolates were sourced from vaginal and other superficial clinical samples, encompassing 18 species of Candida and five strains from other yeast genera.
- Susceptibility testing was performed for sertaconazole (STZ) alongside clotrimazole (CTZ), econazole (ECZ), ketoconazole (KTZ), miconazole (MNZ), fluconazole (FLZ), itraconazole (ITZ), tioconazole (TCZ), amphotericin B (AMB), and flucytosine (5FC).
Main Results:
- Sertaconazole (STZ) exhibited a high rate of susceptibility, with 87.4% of strains (n=160) being susceptible and only one strain (0.5%) showing resistance.
- The percentage of susceptible strains to STZ was notably higher than for most other evaluated antifungal agents.
- Specific Candida species, including Candida albicans and Candida dubliniensis, displayed favorable susceptibility patterns to STZ compared to several other antifungals.
Conclusions:
- In vitro data strongly indicate that sertaconazole (STZ) possesses significant antifungal activity against a broad spectrum of clinically relevant yeasts.
- The high susceptibility rates and lower resistance observed with STZ suggest its considerable therapeutic potential for treating yeast infections.
- Further clinical trials are recommended to validate the in vitro findings and confirm the clinical efficacy of sertaconazole in human subjects.